Muju

Researchers are observing people in South Korea who have chronic heart failure with a left ventricular ejection fraction LVEF of 40% or higher and are receiving finerenone. The study aims to understand the safety and effectiveness of finerenone, a medicine that targets a receptor in the body to reduce harm to the heart, kidneys, and blood vessels. This medication is already approved and prescribed by doctors, and the study focuses on gathering data from everyday medical care without changing treatments. Participants will receive finerenone as prescribed by their doctors during their regular medical visits. The study collects data from those who are starting finerenone treatment for chronic heart failure with LVEF of 40% or greater. There are no additional tests or visits required for the study information is gathered from medical records and interviews during routine care. During the one-year period after joining the study or until participants decide to leave, researchers will monitor any side effects or health issues that may be related to finerenone. They will also track how satisfied doctors are with the treatment over time, including symptom improvement, quality of life, and overall health. Changes in finerenone dosing will be recorded as part of the evaluation of how well the medicine works.

Researchers are studying children and young adults aged 1 to 18 years with chronic kidney disease CKD and proteinuria, a condition where the kidneys leak protein into the urine. This study aims to evaluate the long-term safety of finerenone when added to standard treatments called ACE inhibitors or angiotensin receptor blockers ARBs, which are commonly used to control blood pressure and protect kidney function. The research also seeks to understand how well finerenone can reduce protein levels in urine and support kidney health over time. Participants will receive finerenone in doses adjusted by age and body weight, taken orally for up to 18 months alongside their usual ACEI or ARB treatment. The study includes patients who previously took part in a related trial and will follow them for about 19 months, including a one-month follow-up after treatment ends. The research involves one group receiving finerenone openly without placebo or comparison groups. During the study, participants will attend at least 8 to 12 visits depending on their treatment start status. At these visits, doctors will measure vital signs like blood pressure, heart rate, weight, and height perform physical exams collect blood and urine samples to monitor kidney function and protein levels and conduct heart tests using electrocardiograms and echocardiography. Participants and their caregivers will also answer questions about medication use, side effects, and overall well-being. Safety will be closely monitored by tracking any medical problems that arise during the trial.

Researchers are observing people with hemophilia A, a genetic bleeding disorder caused by a lack of clotting factor 8 FVIII, who use the drug damoctocog alfa pegol as prescribed by their doctors. The study aims to learn more about the safety of this drug in Korean participants who have previously used other hemophilia A treatments. Hemophilia A can cause excessive bleeding after injury or surgery, and damoctocog alfa pegol replaces the missing FVIII to help prevent or treat bleeding episodes. Participants will continue their usual treatment with damoctocog alfa pegol during routine medical care, following approved product guidelines. No study drug is provided by the researchers, and no changes to healthcare are made for study purposes. Data collection occurs over about 8 months for each participant, from December 2023 to March 2026, with information gathered from health records and routine clinic visits. Participants are involved through their regular medical visits, with no extra tests or visits required for the study. Researchers will monitor and collect data on any medical problems, including various types of adverse events and reactions, during treatment. They will also track bleeding episodes and treatment use, comparing with previous FVIII products. Safety data will be collected continuously during the 36-week observational period without interfering with standard care.

Researchers are collecting and studying data from adults with chronic kidney disease CKD and type 2 diabetes T2D who are receiving finerenone as part of their routine medical care. CKD is a long-term condition where the kidneys gradually lose their ability to filter waste, and T2D can lead to kidney damage due to high blood sugar levels. The study aims to better understand the characteristics and treatment patterns of people starting finerenone in South Korea. The study observes participants who have recently started or will start finerenone treatment prescribed by their doctor. Finerenone is a medication that blocks proteins which may harm the kidneys and heart. Researchers are collecting information about clinical characteristics, reasons for starting or stopping finerenone, treatment duration and dosing, and other medications taken alongside finerenone. Data will be gathered through medical records and interviews during routine visits. Participants are involved for up to 12 months or until finerenone treatment stops early. The study will monitor any medical problems, including adverse events and high potassium levels hyperkalemia that may require additional care such as dialysis or hospitalization. Researchers will analyze clinical data, treatment patterns, and safety information to better understand finerenone use in this population.

Researchers are observing the safety of darolutamide in Korean men with two types of prostate cancer non-metastatic castration-resistant prostate cancer nmCRPC, which has not spread and does not respond to testosterone reduction, and metastatic hormone-sensitive prostate cancer mHSPC, which has spread but can be treated by lowering testosterone. Darolutamide is a drug that blocks hormones from binding to androgen receptors in prostate cells, potentially slowing cancer growth. This observational study focuses on men who have already been prescribed darolutamide by their doctors. Participants will continue their usual care while being observed for up to one year. They will visit their doctors every 2 to 4 months for scans to monitor cancer and blood tests. Researchers will collect data from medical records about adverse events, medication use, and how well darolutamide is working. The dose and duration of darolutamide are determined by their doctors following local guidelines. Throughout the study, doctors will track the number and severity of any adverse events or drug reactions, including serious cases, from the time patients consent until 30 days after treatment ends. Participants will answer questions about their medications and health. Researchers will also monitor cancer progression and survival outcomes. The entire study will last about six years, with each participant involved for about one year.

Researchers are observing people with chronic heart failure with reduced ejection fraction HFrEF, a condition where the heart pumps blood less effectively. This study focuses on patients in Korea who are prescribed vericiguat, a drug that increases the activity of an enzyme important for heart and blood circulation. The purpose is to collect real-world data on how vericiguat is used and its safety in regular medical practice. Participants receive vericiguat as prescribed by their doctors according to approved guidelines, without any intervention from the study team. Data collection includes medical records and routine practice visits. Participants are observed for up to 12 months or until death or withdrawal, whichever occurs first. The study tracks treatment patterns, including dose levels and duration of vericiguat use. During the study, researchers will monitor all adverse events, whether or not they are related to the drug. They will also collect information on serious heart-related outcomes such as death and hospital stays due to heart failure. The main outcome measures include the number of adverse events and cardiovascular events over the observation period. This approach helps understand vericiguats use and safety in everyday care over about one year.

Researchers are investigating how well the drug VITRAKVI generic name larotrectinib works and how well patients tolerate it in real-world use for those with TRK fusion cancer. This cancer type involves a genetic change called an NTRK gene fusion that can cause tumors to grow. The study includes adults and children with locally advanced or metastatic solid tumors that have this specific gene fusion, reflecting a variety of common and rare cancers. Patients enrolled in this observational study are those for whom their doctors have decided to treat with larotrectinib. Treatments and medical care follow local standard practices without interference from the study. Participants are grouped based on cancer types like gastrointestinal, head and neck, soft tissue sarcoma, CNS, lung, melanoma, pediatric tumors, and others. Data on treatments, other medications, disease changes, and health symptoms will be collected during routine care. Participants will be observed for 24 to 60 months. Researchers will collect information on treatment side effects up to 30 days after treatment ends and monitor responses, disease control, survival, doses, and developmental milestones for up to 8 years. Medical records, including height, weight, neurological assessments, and Tanner stage will be reviewed as part of this long-term observation.